APTIOM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $99,587 | 5,442 | 1,885 |
| 2023 | $347,345 | 16,601 | 3,786 |
| 2022 | $295,489 | 12,848 | 3,703 |
| 2021 | $221,809 | 10,611 | 3,651 |
| 2020 | $345,543 | 12,215 | 3,112 |
| 2019 | $1.3M | 30,709 | 4,932 |
| 2018 | $3.0M | 43,000 | 6,774 |
| 2017 | $3.6M | 47,994 | 7,846 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.4M | 2,588 | 58.1% |
| Food and Beverage | $2.8M | 171,531 | 30.4% |
| Travel and Lodging | $774,946 | 3,825 | 8.4% |
| Unspecified | $157,313 | 368 | 1.7% |
| Space rental or facility fees (teaching hospital only) | $57,875 | 34 | 0.6% |
| Consulting Fee | $53,450 | 10 | 0.6% |
| Education | $20,057 | 1,064 | 0.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures | Sunovion Pharmaceuticals Inc. | $83,383 | 0 |
| A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug | Sunovion Pharmaceuticals Inc. | $64,000 | 1 |
| Eslicarbazepine Acetate Monotherapy Long Term Study | Sunovion Pharmaceuticals Inc. | $9,232 | 1 |
| STUDY TO EVALUATE SERUM FREE THYROXINE (FT4) AND FREE TRIIODOTHYRONINE (FT3) MEASUREMENTS FOR SUBJECTS TREATED WITH ESLICARBAZEINE ACETATE (ESL) | Sunovion Pharmaceuticals Inc. | $698.67 | 0 |
Top Doctors Receiving Payments for APTIOM — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurology | Houma, LA | $24,064 | 100 |
| , MD | Neurodevelopmental Disabilities | Hackensack, NJ | $23,737 | 47 |
| , M.D | Neurology | Apple Valley, CA | $23,690 | 77 |
| , M.D | Neurology | Dallas, TX | $23,167 | 118 |
| , MD | Neurology | Nashville, TN | $23,165 | 38 |
| , MD | Pediatrics | Charlotte, NC | $23,093 | 92 |
| , MD | Neurology | Asheville, NC | $22,736 | 68 |
| , MD | Neurology | Fort Worth, TX | $22,690 | 70 |
| , M.D | Neurology | West Columbia, SC | $22,519 | 61 |
| , D.O | Neurology | Columbia, MO | $22,390 | 48 |
| , M.D | Neurology | Dallas, TX | $21,817 | 327 |
| , MD | Clinical Neurophysiology | New Hyde Park, NY | $21,465 | 44 |
| , M.D | Neurology | Pittsburgh, PA | $21,403 | 64 |
| , M.D | Neurology | Austin, TX | $20,832 | 116 |
| , M.D | Neurology | Los Angeles, CA | $20,652 | 50 |
| , MD | Neurology with Special Qualifications in Child Neurology | Tucson, AZ | $20,411 | 76 |
| , MD | Neurology | Pismo Beach, CA | $20,253 | 75 |
| , MD | Clinical Neurophysiology | Charlotte, NC | $19,564 | 29 |
| , M.D | Neurology | Durham, NC | $19,196 | 26 |
| , M.D | Neurology | Fulton, MD | $18,844 | 160 |
| , DO, MBA | Neurology | Marquette, MI | $18,754 | 38 |
| , MD | Neurology | Toms River, NJ | $18,001 | 95 |
| , M.D | Neuromusculoskeletal Medicine & OMM | Asheville, NC | $17,788 | 45 |
| , MD | Geriatric Medicine | Brooksville, FL | $17,677 | 33 |
| , MD | Neurology | Edison, NJ | $17,035 | 91 |
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $8.8M
- Sumitomo Pharma America, Inc. $446,932
Product Information
- Type Drug
- Total Payments $9.2M
- Total Doctors 16,725
- Transactions 179,420
About APTIOM
APTIOM is a drug associated with $9.2M in payments to 16,725 healthcare providers, recorded across 179,420 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $99,587 was paid across 5,442 transactions to 1,885 doctors.
The most common payment nature for APTIOM is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5.4M, 58.1% of total).
APTIOM is associated with 4 research studies, including "A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures" ($83,383).